Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imsidolimab in moderate to severe acne vulgaris
NCT04856917Phase 2Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- May 2021
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of imsidolimab in acne vulgaris, sponsored by Vanda Pharmaceuticals Inc.. Started May 2021; status: completed.
02
Drugs
imsidolimab
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT04856917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856917.